NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for high unmet medical needs. Their primary focus is on severe central nervous system (CNS) disorders, particularly suicidal depression and post-traumatic stress disorder (PTSD). The company's lead program, NRX-101, is an oral, fixed-dose combination of D-cycloserine and lurasidone, which targets the brain's NMDA receptor. NRX-101 has been awarded Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support by the FDA for the treatment of suicidal bipolar depression.

In addition to their CNS focus, NRx Pharmaceuticals is also developing ZYESAMI (aviptadil) for the treatment of critical COVID-19 and other respiratory diseases. ZYESAMI has been granted Fast Track designation by the FDA and is currently undergoing Phase III trials for critical COVID-19 patients. NRx Pharmaceuticals is committed to leveraging its scientific expertise and innovative approach to bring hope and life-saving therapies to patients with debilitating conditions.

NRx Pharmaceuticals is a clinical biopharma company dedicated to developing innovative treatments for serious, life-threatening conditions with major unmet medical needs, specifically focusing on severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD). They leverage proven science and clinical expertise to quickly identify and apply medical solutions while simultaneously focusing on expanding therapeutic potential for the future. Their mission is to bring hope to life by providing life-saving medicines for those with unmet medical needs.

NRx Pharmaceuticals promotes a culture focused on innovation, collaboration, and bringing hope to life. They are an agile and specialized CNS biopharma company driven by a mission to address high unmet medical needs. The company emphasizes leveraging proven science and clinical expertise to identify and apply medical solutions as quickly as possible, while simultaneously focusing on expanding therapeutic potential for the future. They foster a team-oriented environment with a commitment to scientific advancement and making untreatable diseases treatable.